Guimarães S, Moura D
Institute of Pharmacology and Therapeutics, Faculty of Medicine, Alameda Hernani Monteiro, Porto, Portugal.
Pharmacol Rev. 2001 Jun;53(2):319-56.
The total and regional peripheral resistance and capacitance of the vascular system is regulated by the sympathetic nervous system, which influences the vasculature mainly through changes in the release of catecholamines from both the sympathetic nerve terminals and the adrenal medulla. The knowledge of the targets for noradrenaline and adrenaline, the main endogenous catecholamines mediating that influence, has recently been greatly expanded. From two types of adrenoceptors (alpha and beta), we have now nine subtypes (alpha1A, alpha1B, alpha1D, alpha2A/D, alpha2B, alpha2A/D, beta1, beta2, and beta3) and two other candidates (alpha1L and beta4), which may be conformational states of alpha1A and beta1-adrenoceptors, respectively. The vascular endothelium is now known to be more than a pure anatomical entity, which smoothly contacts the blood and forms a passive barrier against plasma lipids. Instead, the endothelium is an important organ possessing at least five different adrenoceptor subtypes (alpha2A/D, alpha2C, beta1, beta2, and beta3), which either directly or through the release of nitric oxide actively participate in the regulation of the vascular tone. The availability of transgenic models has resulted in a stepwise progression toward the identification of the role of each adrenoceptor subtype in the regulation of blood pressure and fine-tuning of blood supply to the different organs: alpha2A/D-adrenoceptors are involved in the central control of blood pressure; alpha1-(primarily) and alpha2B-adrenoceptors (secondarily) contribute to the peripheral regulation of vascular tone; and alpha2A/D- and alpha2C-adrenoceptors modulate transmitter release. The increased knowledge on the involvement of vascular adrenoceptors in many diseases like Raynaud's, scleroderma, several neurological degenerative diseases (familial amyloidotic polyneuropathy, Parkinson disease, multiple-system atrophy), some kinds of hypertension, etc., will contribute to new and better therapeutic approaches.
血管系统的总外周阻力和区域外周阻力及容量由交感神经系统调节,交感神经系统主要通过改变交感神经末梢和肾上腺髓质中儿茶酚胺的释放来影响血管系统。介导这种影响的主要内源性儿茶酚胺去甲肾上腺素和肾上腺素的作用靶点的知识最近有了很大扩展。从两种肾上腺素能受体(α和β),我们现在有九种亚型(α1A、α1B、α1D、α2A/D、α2B、α2A/D、β1、β2和β3)以及另外两种候选亚型(α1L和β4),它们可能分别是α1A和β1肾上腺素能受体的构象状态。现在已知血管内皮不仅仅是一个纯粹的解剖实体,它与血液平滑接触并形成对血浆脂质的被动屏障。相反,内皮是一个重要器官,拥有至少五种不同的肾上腺素能受体亚型(α2A/D、α2C、β1、β2和β3),这些亚型直接或通过一氧化氮的释放积极参与血管张力的调节。转基因模型的出现使得在确定每种肾上腺素能受体亚型在血压调节和不同器官血液供应微调中的作用方面有了逐步进展:α2A/D肾上腺素能受体参与血压的中枢控制;α1(主要)和α2B肾上腺素能受体(次要)有助于血管张力的外周调节;α2A/D和α2C肾上腺素能受体调节递质释放。对血管肾上腺素能受体参与许多疾病(如雷诺病、硬皮病、几种神经退行性疾病(家族性淀粉样多神经病、帕金森病、多系统萎缩)、某些类型的高血压等)的了解增加,将有助于开发新的更好的治疗方法。